Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate versus placebo for prevention of bone loss in postmenopausal women with breast cancer receiving aromatase inhibitors
2006-006943-29Phase 3Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Actonel with Placebo (2 arms). Primary endpoint: Main objective endpoint. Started Mar 2009; status: active.
02
Drugs
risedronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006943-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006943-29.